Clinigen Takes Aim At Unlicensed-To-Licensed Strategy With Quantum Buy

Extending its business in continental Europe, in niche generics and in the further development of unlicensed medicines are some of the drivers of Clinigen's latest proposed acquisition.

Target
Some patients need unlicensed medicines for their condition • Source: Shutterstock.

The UK pharmaceutical services company. Clinigen Group PLCis planning to acquire Quantum Pharma PLC in a cash-and-share deal valued at £150.3m ($199.5m), enlarging Clinigen's activities in the ethical supply of unlicensed medicines in the UK and continental Europe, and strengthening its role in commercializing medicine.

The interest of Clinigen in Quantum became public in the middle of last month, and the two AIM-listed companies have...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.